Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Ophthalmology That Protect the Drug Margin and Grow the Surgical Franchise

Ophthalmology runs on a rare split economy: a Part B anti-VEGF buy-and-bill book measured in ASP spreads, and a surgical and cash-pay franchise measured in throughput and mix. Fulcrum Health Partners advises retina groups, comprehensive practices, ASC-integrated platforms, and PE-backed MSOs across drug-margin defense, cataract and premium/refractive economics, and commercial rate strategy — converting fragile top-line into defensible contribution margin.

Model Your Reimbursement Opportunity → Speak with an Ophthalmology Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

>60%

Of a retina practice's revenue can flow through Part B drug buy-and-bill

ASP+6%

Statutory add-on on Part B drugs — before sequestration erosion

Step Tx

Payers now gate anti-VEGF with step therapy & prior authorization

MSO

PE roll-ups consolidating ophthalmology into platform assets

The Ophthalmology Reimbursement Landscape

A big top line built on a thin, contested drug margin.

In ophthalmology, gross revenue and real margin are two different stories — the anti-VEGF book inflates the top line while the true economics sit in surgical mix, site of service, and cash-pay upgrades.

Retina practices acquire aflibercept, ranibizumab, and bevacizumab — and now their biosimilars — and bill them buy-and-bill under Part B at ASP plus a statutory add-on that sequestration has quietly compressed. A single injection can carry thousands of dollars of drug cost passing straight through the P&L, so headline revenue balloons while the retained spread stays narrow and exposed to ASP resets, biosimilar substitution, step therapy, and white-bagging mandates that move the drug to the pharmacy benefit entirely.

Meanwhile the durable economics live elsewhere: cataract volume and its migration to the ASC site of service, premium-IOL and refractive cash upgrades that sit outside the fee schedule, MIGS glaucoma procedures, and diagnostics such as OCT and optometric co-management. The same practice can be worth dramatically different amounts depending on how the drug book is contracted, how surgical cases are sited, and how cash-pay is priced — and that is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/Medicare Part B ASP methodology and public payer data, 2024–2026.

Gross Revenue vs. Retained Margin — Illustrative

Where ophthalmology economics actually sit

Retina anti-VEGF buy-and-bill

Cataract & ASC surgical

Diagnostics (OCT)

Premium / refractive cash-pay

The drug book fills the top line; surgical mix and cash-pay fill the margin. Fulcrum quantifies both — and defends the spread.

Our Ophthalmology Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide ophthalmology margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule — professional, facility/ASC, and Part B drug — then benchmark your ophthalmology reimbursement against Medicare and against market, quantifying exactly where the anti-VEGF spread, cataract rates, and premium carve-outs sit and what the opportunity is worth.

Contract & fee schedule digitization

ASP add-on & drug-margin benchmarking

% of Medicare benchmarking

Cataract & MIGS rate analysis

ASC vs. office site-of-service review

EOB & payment variance analysis

Underpayment identification

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to protect anti-VEGF drug reimbursement, lift commercial surgical rates, and secure premium-IOL and refractive terms across every payer — from renewals to executive payer meetings.

Commercial rate improvement

Drug reimbursement & ASP protection

ASC & facility fee strategy

Premium-IOL & refractive terms

Contract renewals & redlining

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT-, J-code-, and payer-level modeling that turns claims and contracts into scenario analysis — biosimilar substitution, ASP resets, site-of-service shifts, and surgical mix — with revenue forecasts your executives can act on.

CPT & J-code reimbursement modeling

Biosimilar & ASP scenario analysis

Site-of-service (office vs. ASC) modeling

Surgical mix & premium-IOL forecasting

Payer mix & revenue projection

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing ophthalmology and retina groups are actually paid on injections, cataract, and diagnostics — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Anti-VEGF & cataract rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers

Covered Lives & Market Intelligence

We map covered lives, payer penetration, referral patterns, and optometric co-management across your market so you prioritize the negotiations, ASC investments, and drug-book decisions that move the most margin.

Covered-lives analysis

Payer penetration & market share

Referral & co-management dynamics

ASC catchment & site strategy

Demographic & disease-prevalence trends

Commercial opportunity identification

06 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers deny injections, impose step therapy, force white-bagging, downcode surgical claims, or delay drug payment, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Drug denial & step-therapy challenges

White-bagging & buy-and-bill disputes

Downcoding & policy challenges

Escalation support

Contract enforcement

07 The Challenge — Earned revenue that never arrives

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, ASP-based allowables, and EOB/remittance data to detect variances on both sides — recovering underpaid injections and surgical claims while remediating overpayment exposure so leakage and risk both stop.

Contract compliance auditing

Drug & surgical underpayment detection

Overpayment & refund exposure review

Automated EOB/remit analytics

Recovery & appeals strategy

Root-cause revenue-integrity programs

Reimbursement Intelligence in Action

Your practice economics, by ophthalmology profile

Fulcrum turns your claims, drug-utilization, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view spanning professional/facility services and Part B drug buy-and-bill.

Comprehensive Ophthalmology · Payer Mix & Revenue Live Sample

Payer Mix (by active patients)

Net Revenue by Payer — Services vs. Part B Drug Buy-and-Bill

Professional & facility services netPart B drug (buy-and-bill) & cash-pay

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, drug-utilization, and contract data by CPT, J-code, payer, and site of service.

The Forces Reshaping Ophthalmology Economics

The strategic questions every ophthalmology leader now faces

Beyond the fee schedule, these are the dynamics that decide ophthalmology margin — and where Fulcrum builds the strategy.

Anti-VEGF Drug Margin & ASP Dynamics

Defending the buy-and-bill spread on aflibercept, ranibizumab, and bevacizumab as ASP resets and sequestration compress the statutory add-on quarter after quarter.

Biosimilar Adoption Economics

Deciding when and how to adopt anti-VEGF biosimilars — balancing lower acquisition cost, ASP dilution, payer preferencing, and the impact on absolute margin per injection.

Prior Authorization & Step Therapy

Managing the administrative tax and revenue delay as payers gate retina injections behind step therapy and prior authorization on the most costly agents.

Medical vs. Pharmacy Benefit & White Bagging

Resisting or negotiating white-bagging mandates that move the drug to the pharmacy benefit and strip buy-and-bill economics out of the practice entirely.

Site of Service: Office, ASC & Premium Cash-Pay

Optimizing cataract and MIGS migration to the ASC, and pricing premium-IOL and refractive upgrades that sit outside the fee schedule as true margin.

PE Consolidation into MSO Platforms

Competing with — and evaluating alignment against — private-equity-backed ophthalmology MSOs consolidating retina and comprehensive practices into platform assets.

Ophthalmology Reimbursement Calculator

See what optimized anti-VEGF buy-and-bill economics are worth

Model the annual uplift from moving the commercial reimbursement on your retina anti-VEGF injection book toward market and optimized levels — expressed as an effective rate on the buy-and-bill book (ASP-plus style). Surgical, ASC, and premium/refractive gains are additive.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual anti-VEGF retina injection revenue (drug buy-and-bill + administration)

Current commercial rate on the injection book (% of Medicare / ASP baseline)

Optimized commercial rate (% of Medicare) — 125%

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of injection revenue

3-year cumulative

Directional estimate for discussion only. Models commercial rate improvement on the anti-VEGF buy-and-bill book; ASP add-on protection, biosimilar mix, cataract/ASC site-of-service, and premium/refractive cash-pay gains are additive. A Fulcrum analysis models your actual contracts, drug utilization, and payer mix.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with ophthalmology and retina groups and platforms.

Retina-Focused Group

$3.9M

recovered anti-VEGF drug margin

Situation: the group's commercial injection reimbursement had drifted below acquisition-plus economics as biosimilars diluted ASP. Result: we repriced the buy-and-bill book, protected the add-on, and recovered underpaid J-code claims — restoring per-injection contribution margin.

Comprehensive Ophthalmology + ASC

16%

commercial surgical rate improvement

Situation: cataract and MIGS rates sat well below market and cases were under-sited. Result: benchmarking and renegotiation lifted commercial surgical reimbursement and shifted eligible volume to the ASC — without adding a single provider.

PE-Backed MSO Platform

8 pts

EBITDA margin from contract harmonization

Situation: a multi-state roll-up carried a patchwork of legacy drug and surgical contracts. Result: we harmonized terms, defended the drug spread, and remediated systematic underpayments — lifting platform EBITDA ahead of a recapitalization.

Why Ophthalmology Leaders Choose Fulcrum

The advisor that speaks ophthalmology's economic language

Independent by design and fluent in the split economy of the specialty — anti-VEGF buy-and-bill and ASP dynamics, cataract and ASC site-of-service, premium/refractive cash-pay, and commercial rate strategy — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Retina & Drug-Margin Fluency

Fluent in ASP, buy-and-bill, and biosimilar economics.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

CPT, J-Code & ASC Analytics

Modeling down to the code and the site of service.

National Payer Experience

Insight into payer drug and surgical policy in every market.

Premium & Refractive Insight

Pricing cash-pay upgrades outside the fee schedule.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Ophthalmology insights & analysis

Executive briefings on the forces moving ophthalmology economics — anti-VEGF drug margin and ASP dynamics, biosimilar adoption, cataract and ASC site-of-service, premium/refractive cash-pay, and PE consolidation.

Defending the Anti-VEGF Buy-and-Bill Margin → Biosimilars, ASP & the Retina Drug Economy →

Explore Ophthalmology Insights →